Table 1.
Characteristics of patients at inclusion in the study (N = 1,317).
| Total patients | |
|---|---|
| Gender | |
| Female | 516 (39.2%) |
| Male | 801 (61.8%) |
| Age at inclusiona (years) | |
| Age, median (IQR) | 42 (37–48) |
| Baseline CD4 cell-count at inclusion (cells per µL)b | |
| Mediane, IQR | 496 (354–677) |
| <200 | 99 (7.6%) |
| 201–350 | 222 (17%) |
| >350 | 986 (75.4%) |
| Duration of PI-based regimen (years) | |
| Median, IQR | 4.98 (2.74–6.67) |
| <2 | 204 (15.5%) |
| >2 | 1,113 (84.5%) |
| Second-line regimenc | |
| LPV-containing | 193 (14.8%) |
| ATV-containing | 1,090 (83.5%) |
| ATV + LPV-containing | 23 (1.7%) |
| Adherence leveld | |
| Low adherence | 41 (3.1%) |
| Moderate adherence | 178 (13.5%) |
| High adherence | 1,096 (83.4%) |
aN = 1,304.
bN = 1,307.
cN = 1,306.
dN = 1,315.